Tecvayli (teclistamab-cqyv) vs Aphexda (motixafortide)
Tecvayli (teclistamab-cqyv) vs Aphexda (motixafortide)
Tecvayli (teclistamab-cqyv) is a bispecific antibody designed for the treatment of relapsed or refractory multiple myeloma, targeting both BCMA on myeloma cells and CD3 on T-cells to promote cancer cell killing. Aphexda (motixafortide), on the other hand, is a CXCR4 antagonist aimed at mobilizing cancer cells from the bone marrow and sensitizing them to chemotherapy and immunotherapy, and it is being investigated for multiple cancer types, including multiple myeloma. When deciding between the two, a patient should consider the specific indication, mechanism of action, the stage and specifics of their disease, and consult with their healthcare provider to determine which medicine aligns best with their treatment goals and medical history.
Difference between Tecvayli and Aphexda
Metric | Tecvayli (teclistamab-cqyv) | Aphexda (motixafortide) |
---|---|---|
Generic name | Teclistamab-cqyv | Motixafortide |
Indications | Relapsed or refractory multiple myeloma | Enhancement of stem cell mobilization |
Mechanism of action | Bispecific antibody targeting BCMA and CD3 | CXCR4 antagonist |
Brand names | Tecvayli | Aphexda |
Administrative route | Subcutaneous injection | Subcutaneous injection |
Side effects | Cytokine release syndrome, infections, neutropenia | Diarrhea, nausea, injection site reactions |
Contraindications | None specifically listed; use caution in patients with infections or a history of recurrent infections | None specifically listed; use with caution in patients with thrombocytopenia or coagulation disorders |
Drug class | Bispecific monoclonal antibody | CXCR4 antagonist |
Manufacturer | Janssen Biotech, Inc. | BioLineRx Ltd. |
Efficacy
Tecvayli (teclistamab-cqyv) for Multiple Myeloma
Tecvayli, also known by its generic name teclistamab-cqyv, is an innovative therapeutic agent that has shown promise in the treatment of multiple myeloma. Multiple myeloma is a type of cancer that affects plasma cells, which are a kind of white blood cell found in the bone marrow. Tecvayli is a bispecific antibody, which means it is designed to bind to two different antigens simultaneously. In the case of Tecvayli, it targets both CD3 on T-cells and BCMA on myeloma cells, thereby bringing these cells into close proximity and promoting the destruction of the cancer cells by the immune system.
The efficacy of Tecvayli has been evaluated in clinical trials involving patients with relapsed or refractory multiple myeloma. The results have demonstrated a significant clinical benefit, with a portion of patients achieving a partial or complete response to the treatment. This suggests that Tecvayli can be an effective option for patients who have exhausted other treatments, offering a new avenue for managing the disease and potentially improving patient outcomes.
Aphexda (motixafortide) for Multiple Myeloma
Aphexda, with the generic name motixafortide, is a novel chemokine-based therapy that has been investigated for its potential in treating multiple myeloma. Motixafortide is a CXCR4 antagonist, which means it interferes with the CXCR4 receptor, a critical element in the homing and retention of myeloma cells within the bone marrow microenvironment. By disrupting the interaction between myeloma cells and their niche, motixafortide aims to sensitize the cancer cells to chemotherapy and other anti-myeloma treatments.
While Aphexda is not primarily a stand-alone treatment for multiple myeloma, its efficacy has been assessed in combination with other therapies. Clinical studies have shown that when used in conjunction with established treatments, motixafortide can enhance the response rates and deepen the responses achieved. This synergistic effect makes it a valuable addition to the therapeutic arsenal against multiple myeloma, particularly for patients who may not respond adequately to conventional treatment modalities alone.
Regulatory Agency Approvals
Tecvayli
Aphexda
Access Tecvayli or Aphexda today
If Tecvayli or Aphexda are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us